SitemapImpressumDatenschutzerklärungdeutschenglish
MHH Logo

Publikationen

 

 

Poling J, Oezkur M, Kogge K, Mengel M, Niemann H, Winkler M, Haverich A, Wiebe K.

Hyperacute rejection in ex vivo-perfused porcine lungs transgenic for human complement regulatory proteins.

Transplant Int 2006 Mar;19(3):225-232

 

Alexandrova K, Griesel C, Barthold M, Heuft HG, Ott M, Winkler M, Schrem H, Manns MP, Bredehorn T, Net M, Vidal MM, Kafert-Kasting S, Arseniev L.

Large-scale isolation of human hepatocytes for therapeutic application.

Cell Transplant. 2005;14(10):845-53

 

Vitko S, Margreiter R, Weimar W, Dantal J, Kuypers D, Winkler M, Oyen O, Viljoen HG, Filiptsev P, Sadek S, Li Y, Cretin N, Budde K; RAD B201 Study Group.

Three-Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients.

Am J Transplant. 2005; 10: 2521-30. Erratum in: Am J Transplant. 2006 Jan;6(1):243.

 

Winkler ME, Winkler M, Burian R, Hecker J, Loss M, Przemeck M, Lorenz R, Patience C, Karlas A, Sommer S, Denner J, Martin U.

Analysis of pig-to-human porcine endogenous retrovirus transmission in a triple-species kidney xenotransplantation model.

Transpl Int. 2005 12: 848-58.

 

Budde K, Lehne G, Winkler M, Renders L, Lison A, Fritsche L, Soulillou JP, Fauchald P, Neumayer HH, Dantal J; RADW 102 Renal Transplant Study Group.

Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients.

J Clin Pharmacol. 2005; 45: 781-91

 

Budde K, Neumayer HH, Lehne G, Winkler M, Hauser IA, Lison A, Fritsche L, Soulillou JP, Fauchald P, Dantal J; RADW 102 Renal Transplant Study Group.

Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.

Nephrol Dial Transplant. 2004; 2606-14.

 

Bittscheidt H, Bektas H, Winkler M, Klempnauer J.

Impact of donor-recipient MHC matching on experinmental islet allotransplant survival in naïve and presensitized lewis rats.

Transplantation 2004; 78:162-4.

 

Schultheiss D, Lorenz RR, Meister R, Westphal M, Gabouev AI, Mertsching H, Biancosino C, Schlote N, Wefer J, Winkler M, Stief CG, Jonas U.

Functional tissue engineering of autologous tunica albuginea: a possible graft for peyronies`s disease surgery.

European Urology 2004;45:781-6.

 

Przemeck M, Lorenz R, Loss M, Wiebe K, Appiah R, Winkler M, Piepenbrock S:

Effect of semi-invasive cardiovascular monitoring on the perioperative outcome of kidney or lung xenotransplantation in cynomolgus monkeys.

J Exp Animal Science 2003;42:192-202.

 

Schneider A, Attaran M, Gratz KF, Bleck JS, Winkler M, Manns MP, Ott M.

Intraportal infusion of 99mtechnetium-macro-aggregrated albumin particles and hepatocytes in rabbits: assessment of shunting and portal hemodynamic changes.

Transplantation 2003;75:296-302.

 

Loss M, Hecker JM, Vangerow B, Schmistko J, Lorenz R, Kunz R, Jalali A, Piepenbrock S, Klempnauer J, Winkler M.

Pathophysiologie und Therapieansätze der akut vaskulären Abstossungsreaktion (AVR) nach Transplantation h-CD55 transgener Schweinenieren in Cynomolgusaffen.

Transplantationsmedizin 2002;14:206-210.

 

Winkler M.

Inolimomab.

Current opinion in Investigational Drugs. 2002;10:1464-1467

 

Hecker JM, Loss M, Klempnauer J, Winkler M.

C1-Inhibitor for therapy and prophylaxis of acute vascular rejection of porcine kidneys in cynomolgus monkeys.

Transplant. Proc. 2002;34:2382.

 

Przemeck M, Lorenz R, Vangerow B, Klempnauer J, Winkler M, Piepenbrock S.

Pretreatment with C1-Esterase Inhibitor improves cardiovascular stability in small primates undergoing porcine kidney xenotransplantation.

Transplant. Proc. 2002;34:2383

 

Kirchner G, Mueller L, Winkler M, Loss M, Roechte F, Deters M, Christians U, Kaever V, Klempnauer J, Sewing K, Manns M.

Long-term pharmacokinetics of the metabolites of everolimus (SDZ-RAD) and cyclosporine in renal transplant recipients.

Transplant. Proc. 2002;34:2233.

 

Winkler M, Loss M, Przemech M, Lorenz R, Arends H, Hecker J, Kunz R, Jalali A, Schmidtko J, Klempnauer J.

Pig to primate life-supporting xenotransplantation – impact of transgenic donor organs on recipient survival.

Transplantationsmedizin 2002;14:143-145.

 

Lorenz R, Appiah R, Hecker JM, Loss M, Kunz R, Schuettler W, Niemann H, Wiebe K, Kniesch K, Klempnauer J, Winkler M.

Expression of human CD59 in transgenic porcine kidneys prevents Hyperacute rejection in a discordant xenogenic ex vivo hemoperfusion model.

Transplantationsmedizin 2002;14:114-119.

 

Hecker JM, Lorenz R, Appiah R, Vangerow B, Loss M, Kunz R, Schmidtko J, Mengel M, Klempnauer J, Piepenbrock S, Dickneite G, Neidhardt H, Ruckoldt H, Winkler M.

C1-Inhibitor for prophylaxis of xenograft rejection following pig to cynomolgus monkey kidney transplantation.

Transplantation 2002;73:688-94.

 

Winkler M.

Ancient proteins and futuristic surgery: the role of complement in discordant xenograft rejection.

Transplant Proc 2001;33:3862-4.

 

Loss M, Lorenz R, Appiah R, Hecker JM, Klempnauer J, Winkler M.

Disorders of coagulation unrelated to xenograft rejection following pig-to-cynomolgus kidney transplantation.

Transplant Proc 2001;33:3867-8.

 

Jaeger K, Gehrmann A, Juttner B, Heine J, Bartsch S, Przemeck M, Scheinichen D, Ruschulte H, Loss M, Kuse ER, Winkler M.

Leukocyte phagocytosis is impaired during kidney xenotransplantation.

Transplant Proc 2001;33:3869-70.

 

Winkler M, Schmidtko J, Wiebe K.

Which Xenotransplant First: Kidney or Thoracic Organ ?

Transplant Linc 2001;2:46-53.

 

Niemann H, Verhoeyen E, Wonigeit K, Lorenz R, Hecker J, Schwinzer R, Hauser H, Kues WA, Halter R, Lemme E, Herrmann D, Winkler M, Wirth D, Paul D.

CMV early promoter induced expression of hCD59 in porcine organs provides protection against hyperacute rejection.

Transplantation 2001;72:1898-1906

 

Woywodt A, Kielstein JT, Winkler M.

Clinical picture: Subphrenic abscess and rupture of the spleen.

Lancet 2001;358(9285):875

 

Vangerow B, Hecker JM, Lorenz R, Loss M, Przemeck M, Appiah R, Schmidtko J, Jalali A, Rueckoldt H, Winkler M.

CI-Inhibitor for treatment of acute vascular xenograft rejection in cynomolgus recipients of hDAF transgenic porcine kidneys.

Xenotransplantation 2001;8:266-272.

 

Przemeck M, Vangerow B, Loss M, Schmidtko J, Klempnauer J, Ruckoldt H, Piepenbrock S, Winkler M.

Hemodynamic consequences of porcine kidney xenograft reperfusion in cynomolgus monkeys.

Transplantation 2001;71:1512-4.

 

Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS.

Rad in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection.

Transplantation 2001;71:1400-6.

 

Jalali A, Loss M, Kunz R, Schmidtko J, Przemeck M, Lorenz R, Piepenbrock S, Klempnauer J, Winkler M.

Analysis of hematopoesis in cynomolgus recipients of h-CD55 transgenic or unmodified porcine kidneys.

Transplant Proc. 2001;33:736-7.

 

Wiebe K, Poeling J, Meliss R, Loss M, Winkler M, Steinhoff G, Haverich A.

Improved function of transgenic pig lungs in ex vivo lung perfusion with human blood.

Transplant. Proc. 2001;33:773-774.

 

Lorenz R, Loss M, Schmidtko J, Kunz R, Jalali A, Przemeck M, White DJ, Klempnauer J, Winkler M.

Influence of cold ischemia time on hyperacute rejection and delayed graft function of porcine kidneys following discordant xenotransplantation from pig to cynomolgus monkey.

Transplant Proc. 2001;33(1-2):740-1

 

Loss M, Vangerow B, Schmidtko J, Kunz R, Hecker J, Schroder C, Ruckholt H, Kaup FJ, Soin B, Cozzi E, Piepenbrock S, Klempnauer J, White DJ, Winkler M.

Acute vascular rejection of h-DAF transgenic porcine kidneys in immunosuppressed cynomolgus monkeys is associated with systemic and intragraft complement activation.

Transplant Proc. 2001;33:715.

 

Kunz R, Loss M, Schroder C, Dulat H, Schmidtko J, Klempnauer J, Winkler M.

Detection of elicited antiporcine antibodies by FACS and Galalpha1-3Gal-specific ELISA in cynomolgus recipients after porcine kidney transplantation.

Transplant Proc. 2001;33:723-4.

 

Schmidtko J, Loss M, Kilic E, Kunz R, Deiwick A, Metz-Rensing K, Kaup F, Klempnauer J, Helmchen U, Winkler M.

Sequential immunohistological analysis of porcine grafts in cynomolgus recipients after discordant kidney xenotransplantation.

Transplant Proc. 2001;33:783.

 

Kirchner GI, Jacobsen W, Deters M, Christians U, Nashan B, Winkler M, Vidal C, Kaever V, Sewing K, Manns MP

Fast quantification method for sirolimus and its major metabolites.

Transplant. Proc. 2001;33:1091-1092.

 

Winkler M, Loss M, Klempnauer J.

Hyperacute xenograft rejection is not consistent after pig to primate solid organ transplantation.

Transplantation. 2001;71:584-5.

 

Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, Gerbeau C, Cambon N, Boger R, Rordorf C; Everolimus Phase 2 Study Group.

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.

Clinical Pharmacology and Therapeutics 2001;69:48-56.

 

Loss M, Arends H, Winkler M, Przemeck M, Steinhoff G, Rensing S, Kaup FJ, Hedrich HJ, Winkler ME, Martin U.

Analysis of potential PERV transmission in a whole organ xenotransplantation model without interfering microchimerism.

Transplant International 2001;14:31-37.

 

Loss M, Schmidtko J, Przemeck M, Kunz R, Arends H, Jalali A, Lorenz R, Piepenbrock S, Klempnauer J, Winkler M.

A primate model for discordant pig to primate kidney xenotransplantation without hyperacute graft rejection.

J. Inv. Surgery. 2001;14:22-29.

 

Loss M, Przemeck M, Kunz R, Schmidtko J, Cozzi E, White D, Klempnauer J, Winkler M: Langzeittransplantatüberleben nach diskordanter Xeno-Nierentransplantation im präklinischen Modell. Langenbecks

Arch. Chir. 2000 S; 245-248.

 

Winkler M.

Cyclosporin as baseline immunosuppression in solid organ transplantation.

BioDrugs 2000; 14:185-193.

 

Kirchner GI, Winkler M, Mueller L, Vidal C, Jacobsen W, Franzke A, Wagner S, Blick S, Manns MP, Sewing KF.

Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.

Br J Clin Pharmacol. 2000 Nov;50(5):449-454.

 

Loss M, Vangerow B, Schmidtko J, Kunz R, Jalali A, Arends H, Przemeck M, Ruckholt H, Leuwer M, Kaup FJ, Rensing S, Cozzi E, White DJ, Klempnauer J, Winkler M.

Acute vascular rejection is associated with systemic complement activation in a pig-to-primate kidney xenograft model.

Xenotransplantation. 2000 Aug;7(3):186-96.

 

Winkler ME, Martin U, Loss M, Arends H, Rensing S, Kaup FJ, Hedrich HJ, Klempnauer J, Winkler M.

is not transmitted in a discordant porcine-to-cynomolgus xenokidney transplantation model with long-term survival of organ recipients.

Transplant Proc. 2000 Aug;32(5):1162.

 

Wiebe K, Steinhoff G, Poeling J, Schroder C, Meliss R, Winkler M, Haverich A.

Ex vivo perfusion of swine lungs: lung function in a pig-to-human model of xenotransplantation.

Transplant Proc. 2000;32:1149-1150.

 

Loss M, Przemeck M, Schmidtko J, Kunz R, Jalali A, Arends H, Lorenz R, Rensing S, Kaup FJ, Jager K, White DJ, Klempnauer J, Winkler M.

Factors determining the onset of hyperacute rejection following discordant porcine-to-cynomolgus monkey kidney xenotransplantation.

Transplant Proc. 2000;32:1098.

 

Loss M, Przemeck M, Schmidtko J, Arends H, Kunz R, Jager K, Jalali A, Rensing S, Kaup J, Cozzi E, White DJ, Klempnauer J, Winkler M.

Long-term survival of cynomolgus monkeys following pig-to-primate kidney xenotransplantation using h-DAF transgenic donor organs.

Transplant Proc. 2000 Aug;32(5):1095-6.

 

Przemeck M, Loss M, Vangerow B, Ruckoldt H, Klempnauer J, Winkler M, Piepenbrock S.

Perioperative monitoring of cardiac function during discordant pig-to-primate kidney xenotransplantation using transpulmonary thermodilution.

Transplant Proc. 2000 Aug;32(5):1086.

 

Kunz R, Loss M, Schwinzer R, Rensing S, Kaup J, Klempnauer J, Winkler M.

Analysis of antiporcine antibodies in cynomolgus recipients of porcine kidneys on cyclophosphamide-based immunosuppression.

Transplant Proc. 2000 Aug;32(5):866.

 

Loss M, Kunz R, Przemeck M, Schmidtko J, Arends H, Jalali A, Lorenz R, Piepenbrock S, Klempnauer J, Winkler M.

Influence of cold ischemia time, pretransplant anti-porcine antibodies, and donor/recipient size matching on hyperacute graft rejection after discordant porcine to cynomolgus kidney transplantation.

Transplantation. 2000 Mar 27;69(6):1155-9.

 

Neumayer HH, Paradis K, Korn A, Jean C, Fritsche L, Budde K, Winkler M, Kliem V, Pichlmayr R, Hauser IA, Burkhardt K, Lison AE, Barndt I, Appel-Dingemanse S.

Entry-into-humans study with the novel immunosuppressant SDZ RAD in stable renal transplant patients.

Br. J. Clin. Pharmacol. 1999;48:694-703.

 

Jaeger K, Ruschulte H, Heine J, Scheinichen D, Leuwer M, Winkler M, Kuse ER.

Neutrophil respiratory burst following liver transplantation: in vitro effects of granulocyte colony-stimulating factor.

Transplant Infectious Diseases 1999;1:153-156.

 

Kirchner GI, Vidal C, Winkler M, Mueller L, Jacobsen W, Franzke A, Sewing KF.

LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood.

Ther Drug Monit. 1999 Feb;21(1):116-22.

 

Oldhafer KJ, Frerker M, Winkler M, Schmidt U.

Complex inferior vena cava and renal vein reconstruction after abdominal gunshot injury.

J Trauma. 1999;46:721-3.

 

Winkler M, Schlitt HJ.

Xenotransplantation der Leber. Zentralblatt für Chirurgie, 1999; 124: 621-7.

 

Winkler M, Uffmann J, Hubrich V, Schmidt U, Kirchhoff K, Oldhafer K, Tscherne H.

Einsatzbericht Bauchschußverletzung mit Perforation der Vena Cava inferior.

Rettungsdienst 1999;22:38-39.

 

Winkler M, Loss M, Arends H, Martin U, Klempnauer J.

Untersuchungen zur Sicherheit von Xenotransplantaten unter Einsatz von Überlebensmodellen nach diskordanter Xeno-Nierentransplantation im Primaten.

Langenbecks Arch. Chir. 1999:1135-7.

 

Jaeger K, Scheinichen D, Heine J, Ruschulte H, Kuse E, Winkler M, Leuwer M.

GM-CSF increases the respiratory burst of human neutrophils after liver transplantation.

Intensive Care Medicine 1999;25:612-5.

 

Winkler M, Loss M, Ahrens H, Schwinzer R.

Analysis of MHC-Class-II expression on circulating T cells by flowcytometry in patients with acute rejection following solid organ transplantation.

Infusionther Transfusionsmed 1998;25:360-363.

 

Kattner A, Ringe B, Haller GW, Kirchner G, Sewing KF, Winkler M.

Early use and oral absorption of Cyclosporin NeoralR after liver transplantation.

Transplant. Proc. 1998;30:1422-3.

 

Lampen A, Bader A, Bestmann T, Winkler M, Witte L, Borlak JT.

Catalytic activities, protein- and mRNA-expression of cytochrome P 450 isoenzymes in intestinal cell lines.

Xenobiotica 1998;28:429-41.

 

Winkler M, Haller GW, Oldhafer K, Bechstein WO, Maibucher A, Farber L, Ringe B, Neuhaus P, Pichlmayr R.

Cyclosporin new oral formulation (CyA-NOF) for early oral immunosuppressive therapy in liver transplant recipients.

Transplant. Proc 1997;29:544-6.

 

Pichlmayr R, Winkler M, Neuhaus P, McMaster P, Calne R, Otto G, Williams R, Groth CG, Bismuth H.

Three-year follow-up of the european multicenter tacrolimus (FK 506) liver study.

Clin. Transplant. Proc. 1997;29:2499-2502.

 

Winkler M, Haller G, Oldhafer K, Bechstein WO, Kattner A, Maibucher A, Farber L, Ringe B, Christians U, Neuhaus P, Pichlmayr R.

A new oral formulation of cyclosporine for early oral immunosuppressive therapy in liver transplant recipients.

Transplantation 1996;62:1063-8.

 

Haller GW, Winkler M, Bechstein WO, Oldhafer KJ, Ringe B, Maibucher A, Farber L, Pichlmayr R, Neuhaus P.

Absorption of Cyclosporine Neoral early after liver transplantation; is it possible to abandon intravenous cyclosporine application?

Transplant. Proc. 1996;28:2239-40.

 

Oldhafer K, Haller GW, Kattner A, Winkler M, Maibucher A, Farber L, Bechstein WO, Ringe B, Neuhaus P, Pichlmayr R.

Absorption of Cyclosporine Neoral early after liver trans­plan­tation: Influence of bile on oral absorption.

Transplant. Proc. 1996;28:2237-8.

 

Winkler M, Christians U, Baumann J, Gonschior AK, Wonigeit K, Pichlmayr R.

Evaluation of the new Pro-TracR tacrolimus monoclonal whole blood ELISA for monitoring of tacrolimus levels in patients after kidney, heart and liver transplantation.

Therapeutic Drug Monitoring 1996;18:640-6.

 

Gonschior AK, Christians U, Winkler M, Linck A, Baumann J, Sewing KF.

Tacrolimus (FK 506) metabolite pattern in blood from liver and kidney transplant patients.

Clinical Chemistry 1996;42:1426-32.

 

Loss M, Winkler M, Schneider A, Oldhafer K, Manns MP, Pichlmayr R.

Glucose and lipid metabolism in LTX patients under long term Tacrolimus therapy.

Transplant. Proc. 1996;28:1006-7.

 

Kattner A, Winkler M, Oldhafer K, Ringe B, Maibucher A, Pichlmayr R.

CyA-NOF for early oral CyA based immunosuppression in patients after liver transplantation.

Transplant. Proc. 1996;28:900-5.

 

Liebau P, Kuse E, Winkler M, Schlitt HJ, Oldhafer K, Verhagen W, Flik J, Pichlmayr R.

Management of herpes simplex virus type I pneumonia following liver transplantation.

Infection 1996;24:130-5.

 

Armstrong VW, Kaltefleiter M, Luy-Kaltefleiter M, Schutz E, Wieland E, Loss M, Winkler M, Ringe B, Oellerich M.

Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine.

Transplant. Proc. 1995;27:1201-3.

 

Loss M, Winkler M, Schneider A, Brinkmann C, Manns M, Ringe B, Pichlmayr R.

Influence of long term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients.

Transplant. Proc. 1995;27:1136-39.

 

Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E, Christians U, Winkler M, Fitzsimmons WE, Lieberman R, et al.

Consensus Document: Therapeutic Drug Monitoring of Tacrolimus (FK 506).

Therapeutic Drug Monitoring 1995;17:606-614.

 

Winkler M, Christians U.

A Risk-Benefit Assessment of Tacrolimus in Transplantation.

Drug Safety 1995;12:348-57.

 

Winkler M, Pichlmayr R:

Neue Tendenzen in der Immunsuppression nach Organtransplantation.

Jahrbuch Chirurgie 1995, Pabst Verlag München.

 

Winkler M:

Kurzbewertung Tacrolimus (Prograf, FK 506).

Internistische Praxis, 1995:184-186.

 

Gonschior AK, Christians U, Winkler M, Schiebel HM, Linck A, Sewing KF.

Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay.

Therapeutic Drug Monitoring 1995;17:504-510.

 

Winkler M, Wonigeit K, Undre N, Ringe B, Oldhafer K, Christians U, Pichlmayr R.

A comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring.

Transplant. Proc. 1995;27:822-6.

 

Winkler M, Ringe B, Oldhafer K, Kattner A, Farber L, Maibucher A, Wonigeit K, Pichlmayr R.

Influence of bile on cyclosporine absorption from microemulsion formulation in primary liver transplant recipients.

Transplant International 1995;8:324-6.

 

Gonschior AK, Christians U, Braun F, Winkler M, Linck A, Baumann J, Sewing KF.

Measurement of blood concentrations of FK 506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by HPLC-MS and microparticle enzyme immunoassay (MEIA). 

British Journal of Clinical Pharmacology 1994;38:567-71.

 

Winkler M, Ringe B, Baumann J, Loss M, Wonigeit K, Pichlmayr R.

Plasma vs. whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression.

Clinical Chemistry 1994;40:2247-53.

 

Winkler M, Brinkmann C, Jost U, Oldhafer K, Ringe B, Pichlmayr R.

Long term side effects of cyclosporine based immunosuppression in patients after liver transplantation.

Transplant. Proc. 1994;26:2679-82.

 

Kattner A, Winkler M, Oldhafer K, Ringe B, Schneider A, Wietholtz H, Manns M, Pichlmayr R.

Conversion from CyA to CyA-NOF in a cholestatic liver grafted patient with CyA-Malabsorption.

Transplant. Proc. 1994;26:2975-6.

 

Farber L, Maibucher A, Geissler F, Gutzler F, Wiesinger FO, Winkler M.

Favourable Clinical Results of Sandimmun Neoral in malabsorbing liver and heart transplant recipents.

Transplant. Proc. 1994;26:2988-93.

 

[No authors listed] Neuhaus P, Bechstein WO, Blumhardt G, Mc Master P, Mayer D, Buckels J, Calne R, Friend P, Joughin C, Pichlmayr R, Winkler M, Ringe B, Otto G, Bleyl J, Williams R, Devlin J, Grady JO, Groth C, Ericzon B, Duraj F, Bismuth H, Samuel D, Rucay P.

Randomized trial comparing tacrolimus and cyclosporine in prevention of liver allograft rejection.

Lancet 1994;344:423-428.

 

Winkler M, Christians U, Stoll K, Baumann J, Pichlmayr R.

Comparison of different assays for the quantitation of FK 506 levels in blood or plasma. 

Therapeutic Drug Monitoring 1994;16:281-6.

 

Winkler M, Christians U, Sewing KF, Pichlmayr R:

Therapeutic Drug Monitoring in patients under FK 506 immunosuppression.

Klin. Labor. 1994;13:1-6

 

Winkler M, Pichlmayr R, Neuhaus P, McMaster P, Calne R, Otto G, Williams R, Bismuth H, Groth C.

Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation. 

Transplant International 1994;7:S58-S63

 

Trocha K, Winkler M, Haas J, Ringe B, Wurster U, Ehrenheim C.

Neurologic examinations after liver transplantation concerning patients under corticosteroid immunosuppression and either FK 506 or cyclosporine.

Transplant International 1994;7:S43-S49.

 

Winkler M, Ringe B, Rodeck B, Melter M, Stoll K, Baumann J, Wonigeit K, Pichlmayr R.

The use of plasma levels for FK 506 dosing in liver grafted patients.

Transplant International 1994;7:329-33.

 

Winkler M, Ringe B, Schneider K, Maibucher A, Farber L, Wietholtz H, Manns M, Pichlmayr R.

Enhanced bioavailability of cyclosporine A using a new oral formulation in a liver grafted patient with severe cholestasis.

Transplant International 1994;7:147-8.

 

Winkler M, Ringe B, Jost U, Melter M, Rodeck B, Buhr T, Brinkmann C, Pichlmayr R.

Conversion from cyclosporine to FK 506 after liver transplantation.

Transplant International 1993;6:319-24.

 

Jost U, Winkler M, Ringe B, Rodeck B, Pichlmayr R.

FK 506 for treatment of intractable rejection after liver transplantation. 

Transplant. Proc. 1993;25:2686-7.

 

Winkler M, Ringe B, Jost U, Gubernatis G, Pichlmayr R.

Plasma level guided low dose FK 506 therapy in patients with initial liver dysfunction after liver transplantation. 

Transplant. Proc. 1993;25:2688-90

 

Peters DH, Fitton A, Plosker GL, Faulds D., Bennett WE, Biere BE, Fukao K, Ishibashi M, Kay JE, Ochiai T, Remuzzi G, Shapiro R, Thomson AW, Tzakis AG, Venkataramanan R, Winkler M, Zeevi A:  <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />

Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Drugs 1993;46:746-94